Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Integra LifeSciences Holdings Corporation
IART
NASDAQ·Healthcare·Medical - Devices·Mkt cap $1.4B
$18.05
▲ +0.89%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$8.70 - $18.92
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 32.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Extensive product portfolio with approximately 40,000 instrument patterns and specialized surgical tools
- Strong market presence in high-barrier neurosurgery and specialty surgical markets
- Integrated distribution network across hospitals, surgery centers, and healthcare systems globally
- Proprietary regenerative technology and tissue repair solutions with clinical validation
- Established relationships with key opinion leaders and integrated health networks
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Rising demand for neurosurgical procedures driven by aging populations and neurological conditions
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Hot
+87.7% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IART right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
MAY 5, 2026
Reported EPS of $0.54 vs $0.41 consensus (+31.7% surprise). Revenue of $391.9M vs $381.8M expected (+2.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+31.7%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+11%
+4%
-1%
+6%
-2%
+2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$418.2M
$380.8M
$442.6M
$382.7M
$415.6M
$402.1M
$434.9M
$391.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
-1.2%
Wall Street consensus
4 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
$12.00
▼ -33.5% vs $18.05
Latest: Citi · May 28, 2026
1 analyst covering